Cumhur Tekin

Cumhur Tekin

Auto-generated profile, based on publicly available information

Cumhur Tekin

Merck & Co., Inc., Rahway, NJ, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2024 in Annals of Oncology
Verified
Journal Article
Open access
Domenica LorussoDomenica Lorusso
Domenica Lorusso
NCN. Colombo
N. Colombo
CDC. Dubot
C. Dubot
MCM.V. Cáceres
M.V. Cáceres
KHK. Hasegawa
K. Hasegawa
BMB.J. Monk
B.J. Monk
In KEYNOTE-826 (NCT03635567), pembrolizumab plus chemotherapy (± bevacizumab) significantly improved overall survival (OS) and progression-free survival (PFS) in patients with persistent, recurrent, or metastatic cervical cancer. This exploratory analysis examined outcomes in patient subgroups defined by bevacizumab use. Eligible adult patients had persistent, recurrent, or metastatic squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix not previously treated with chemotherapy and not amenable to curative treatment; measurable disease per RECIST v1.1; and an Eastern Cooperative Oncology Group performance status ≤1. Patients were randomized 1:1 to pembrolizumab 200 mg every 3 weeks or placebo for up to 35 cycles plus chemotherapy (± bevacizumab 15 mg/kg). Dual primary endpoints were OS and PFS per RECIST v1.1 by investigator assessment. Outcomes were assessed in subgroups defined by bevacizumab use. Hazard ratios (HRs) and 95% CIs were based on a stratified Cox regression model. 617 patients were randomized (pembrolizumab arm, n=308 [63.6% with bevacizumab]; placebo arm, n=309 [62.5% with bevacizumab]). The most common reason for bevacizumab exclusion was medical contraindication (75.9%). Among patients who received bevacizumab, HRs (95% CIs) for PFS favored the pembrolizumab arm in the PD-L1 combined positive score (CPS) ≥1 (0.56 [0.43-0.73]) and all-comer (0.57 [0.45-0.73]) populations; OS results were 0.60 (0.45-0.79) and 0.61 (0.47-0.80), respectively. Among patients who did not receive bevacizumab, HRs (95% CIs) for PFS also favored the pembrolizumab arm in the PD-L1 CPS≥1 (0.61 [0.44-0.85]) and all-comer (0.69 [0.50-0.94]) populations; OS results were 0.61 (0.44-0.85) and 0.67 (0.49-0.91), respectively. Among patients who received bevacizumab, grade ≥3 treatment-related adverse events occurred in 74.0% of patients in the pembrolizumab arm and 66.8% in the placebo arm. Pembrolizumab plus chemotherapy prolonged PFS and OS and had manageable safety compared with placebo plus chemotherapy in patient subgroups defined by bevacizumab use.

1 January 2024 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
MBMin-Hyun Baek
Min-Hyun Baek
LCLei Chen
Lei Chen
CTCumhur Tekin
Cumhur Tekin
RCRazvan Cristescu
Razvan Cristescu
XJXiao Yang Jin
Xiao Yang Jin
JPJeong-Yeol Park
Jeong-Yeol Park
Baek MH, et al. J Gynecol Oncol. 2024 May;35:e105. https://doi.org/10.3802/jgo.2024.35.e105

1 January 2025 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
YKYong-Man Kim
Yong-Man Kim
Shin NishioShin Nishio
Shin Nishio
SKSe Ik Kim
Se Ik Kim
KHKosei Hasegawa
Kosei Hasegawa
CDCoraline Dubot
Coraline Dubot
BMBradley J. Monk
Bradley J. Monk
Kim YM, et al. J Gynecol Oncol. 2025 Apr;36:e110. https://doi.org/10.3802/jgo.2025.36.e110

5 November 2024 in Oncology and Therapy
Verified
Journal Article
Open access
PDF file
BMBradley J. Monk
Bradley J. Monk
SMSophie van Mens
Sophie van Mens
OHOliver Hale
Oliver Hale
JBJennifer Boer
Jennifer Boer
FHFrank van Hees
Frank van Hees
MMMatthew Monberg
Matthew Monberg
Introduction First-line treatment of persistent, recurrent, or metastatic (advanced) cervical cancer in patients who have a combined positive score (CPS) ≥ 1 with pembrolizumab + chemotherapy versus standard-of-care chemotherapy provides meaningful improvements in overall survival. We conducted a cost-effectiveness analysis from a US payer perspective. A societal perspective scenario was also considered, including productivity gains. Methods The cost-effectiveness of pembrolizumab + chemotherapy versus chemotherapy was assessed using a state-transition model comprising the health states “pre-progression,” “post-progression,” and “death,” with a 1-week cycle length and 50-year time horizon. Patient-level KEYNOTE-826 data informed the efficacy, safety, and health-related quality of life of pembrolizumab + chemotherapy versus chemotherapy at first-line and subsequent treatments. Real-world data were sought to cost subsequent treatments according to US clinical practice. Transition probabilities were derived from parametric survival models fit to time-to-progression, progression-free survival, and post-progression survival patient-level KEYNOTE-826 data. Sensitivity analyses explored the impact on outcomes from variables such as bevacizumab use. Results According to the state-transition model, pembrolizumab + chemotherapy extended mean life expectancy versus chemotherapy from 1.8 to 6.7 life-years. The mean gain of 4.9 life-years/patient was mostly caused by pembrolizumab delaying progression. Total discounted quality-adjusted life-years (QALY) were 5.0 and 1.3 per patient for pembrolizumab + chemotherapy and chemotherapy, respectively (mean gain: 3.7 QALY/patient). Pembrolizumab + chemotherapy had comparable safety outcomes to chemotherapy alone. Total costs incurred were US $320,247 (pembrolizumab + chemotherapy) versus US $105,446 (chemotherapy; mean incremental costs: US $214,801/patient). The incremental cost-effectiveness ratio of pembrolizumab + chemotherapy versus chemotherapy was US $58,446/QALY. Sensitivity analyses showed results were insensitive to bevacizumab use. Including productivity gains led to an incremental cost-effectiveness ratio of US $58,385 per QALY. Conclusions Our model-based analysis suggests that first-line treatment of pembrolizumab + chemotherapy in advanced cervical cancer with a CPS ≥ 1 offers a substantial clinical benefit over standard-of-care chemotherapy alone and is cost-effective at a willingness-to-pay threshold of US $150,000. The approximate doubling of life-years and QALYs associated with pembrolizumab + chemotherapy represents a step improvement in the treatment of advanced cervical cancer. Trial Registration ClinicalTrials.gov Identification Number: NCT03635567.